Phathom Pharmaceuticals Charts Profitable Path After Ramp-Up

Phathom Pharmaceuticals, Inc. ((PHAT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Phathom Pharmaceuticals’ latest earnings call struck an upbeat tone, with management emphasizing sharp revenue growth, tighter cost control, and a strengthened balance sheet. Executives acknowledged persistent headwinds in discounts, coverage, and competition, but framed them as manageable risks against a path to profitability starting in 2026.

Surging Full-Year and Quarterly Revenue

Phathom posted 2025 net revenue of $175.1 million, up 217% year over year and at the high end of guidance, signaling powerful commercial momentum. Fourth-quarter revenue reached $57.6 million, in line with prior indications and representing roughly 16% sequential growth, reinforcing the trajectory into 2026.

Cost Discipline and Lower Cash Burn

Management highlighted aggressive cost controls, with Q4 cash operating expenses excluding stock-based compensation at $50.3 million, comfortably below the sub-$55 million goal. Quarterly cash OpEx has been cut nearly in half over the last three quarters, driving Q4 net cash use down to about $5 million, 64% lower than in Q3.

Stronger Liquidity and Cheaper Debt

Liquidity improved meaningfully after an oversubscribed equity raise in January delivered $130 million in gross proceeds, boosting pro forma cash to just above $250 million to start the year. The company also reworked its term loan, trimming principal to $175 million, lowering the rate to 9.85%, and extending maturity to February 2029 after using about $56 million of cash.

High Margins Despite Accounting Shift

Phathom continues to enjoy attractive economics, reporting roughly 87% gross margin for Q4 and full-year 2025 on its lead product VOQUEZNA. For 2026 the company anticipates about 80% gross margin, with management stressing that the decline is largely an accounting reclassification rather than a change in underlying product profitability.

Commercial Momentum and Sales Force Scaling

Commercial execution remained a focal point as VOQUEZNA surpassed 1.1 million prescriptions through mid-February, reaching more than 230,000 patients. In Q4 alone, around 273,000 prescriptions were filled, and covered scripts rose 21% sequentially, supported by a sales organization now roughly 95% staffed with over 285 of 300 positions filled.

Expanding Distribution and Patient Access

The company is leaning on alternative access channels to drive uptake and affordability, with the Blink network now responsible for more than half of prescriptions and 36% of scripts disbursed as cash pay. A GoodRx cash-pay option, launched in November, gives patients another route to lower out-of-pocket costs while potentially accelerating VOQUEZNA adoption.

Drag from High Gross-to-Net Discounts

A key pressure point remains gross-to-net discounts, which sat at the high end of the 55%–60% band in Q4 and are guided to 55%–59% for 2026. These sizable rebates and discounts materially compress reported net revenue versus underlying gross sales, tempering the economic impact of prescription growth.

Losses Narrow but Profitability Still Ahead

The company is edging closer to breakeven, posting an operating loss excluding stock-based compensation of about $320,000 in Q4, a stark improvement from prior quarters. However, full-year 2025 cash operating expenses of roughly $284 million underscore that absolute spending remains high and will continue to weigh on near-term profitability.

Seasonality and Short-Term Volume Noise

Management cautioned that Q1 is likely to be the weakest quarter, reflecting normal seasonality in the gastrointestinal market. Winter storms and data lags added to near-term volatility in prescription trends, suggesting that quarterly numbers may be choppy even as the longer-term growth curve remains intact.

Medicare Coverage Still Constrained

Investors hoping for a near-term reimbursement catalyst may need patience, as executives do not foresee broad Medicare coverage changes. Incremental gains may come from plan appeals and selective Part D inclusion, but systemic Medicare coverage for VOQUEZNA is not expected in the foreseeable future.

Small Share of a Large PPI Market

Despite its rapid growth, VOQUEZNA still represents a small fraction of the estimated 110 million annual PPI prescriptions in the U.S. With about 1.1 million VOQUEZNA scripts so far, Phathom sees a long runway for market share gains, but capturing a meaningful slice will require sustained conversion efforts against entrenched therapies.

Covenant Timing and Cash Obligations

Phathom detailed revenue-interest financing covenants that will drive a peak cash flow requirement of roughly $130 million through late September 2027. Management believes current cash plus projected operations comfortably cover these obligations, yet the timing and size of the commitments remain an important risk metric for investors to monitor.

Data Visibility and Competitive Landscape

Executives flagged discrepancies between IQVIA prescription data and internal metrics, with third-party sources underreporting more than usual and complicating near-term modeling. On the competitive front, other P-CAB candidates such as tegoprazan are advancing, which could both expand the category and increase uncertainty around future market dynamics.

Guidance Signals Profitable Inflection Ahead

For 2026 Phathom guided net revenue of $320–$345 million, including a $17–$20 million accounting reclassification that shifts part of gross-to-net into cost of goods sold, with gross margin around 80% and gross-to-net at 55%–59%. Cash operating expenses are seen at $235–$255 million, about 14% below 2025 at the midpoint, supporting an outlook for operating profitability excluding stock-based compensation beginning in Q3 2026 and for the full year, and cash-flow positivity in 2027, with revenue weighted 40% to the first half and 60% to the second.

Phathom’s earnings call painted a picture of a company transitioning from heavy investment to a more disciplined, scalable growth phase, underpinned by strong VOQUEZNA uptake and improving unit economics. While high discounts, limited Medicare coverage, and looming covenants remain watchpoints, management’s confidence in hitting profitability milestones by 2026–2027 offers a compelling, though execution-dependent, equity story.